본문 바로가기
본문

과제정보

과제명, 기관명, 담당부서, 전화번호, 연구기간, 연구분야, 과제개요의 정보를 제공합니다.
과제명 의약품등 안전관리 기본제도 개선 등 연구
기관명 식품의약품안전처 담당부서 식품의약품안전평가원 연구기획조정과
전화번호 연구기간 2004-04-14 ~ 2004-11-30
연구분야 의약품안전
과제개요 의약품등 안전관리 기본제도 개선 등 연구

계약정보

수행기관, 수행연구원, 계약일자, 계약방식, 계약금액의 정보를 제공합니다.
수행기관 한국보건사회연구원
수행연구원 이의경 계약일자  
계약방식 일반경쟁입찰에 의한 계약 계약금액 45000000원

연구결과정보

제목, 연구보고서, 공개제한근거, 비공개사유, 연구보고서, 목차, 주제어, 공헌자, 제작일, 발행년도의 정보를 제공합니다.
제목 의약품등 안전관리 기본제도 개선 등 연구
연구보고서 04032기본사750.pdf
목차
    연구사업 최종보고서 요약문

    Project Summary

    요 약 ··························································································································· 1

    제1장 서 론 ················································································································ 22
    제1절 연구의 배경 및 목적 ······················································································· 22
    제2절 연구의 목적 및 범위 ······················································································· 24
    제3절 연구 방법 ········································································································· 25

    제2장 미래 환경변화와 의약품 안전관리 목표 ························································ 27
    제1절 미래의 환경 변화와 안전관리 수요 전망 ······················································· 27
    제2절 의약품 안전관리의 현 위치 ············································································ 37
    제3절 의약품 안전관리의 목표 ················································································· 45

    제3장 총체적인 품질시스템(Qualiyt System) 구축 ················································· 49
    제1절 GMP 제도 및 약사 감시 ················································································· 51
    제2절 DMF 제도의 수준 향상을 통한 원료의약품 질 관리 ····································· 69
    제3절 생물학적동등성 제도의 확대 및 질적 수준 향상 ·········································· 92
    제4절 위탁제조의 품질보증체계 구축 ······································································105
    제5절 품질시스템(Quality System)으로의 개념 재정립 ··········································111

    제4장 안전성(Safety)·유효성(Efficacy) 확보를 위한 포괄적 네트워크 구축 ·········157
    제1절 임상시험제도의 선진화 ··················································································158
    제2절 시판후 의약품 안전관리제도(PMS)의 개선 ··················································196
    제3절 전임상 시험제도의 선진화 ············································································· 256
    제4절 표시기재(Labelling) 관리 ················································································ 260
    제5절 안전성·유효성에 관한 논의의 흐름 ································································ 264

    제5장 의약품 안전관리 기본틀의 재정립 ································································· 275
    제1절 리스크관리체계의 정립 ·················································································· 275
    제2절 품목허가 및 업허가의 분리 ············································································ 309
    제3절 의약품 분류체계의 탄력적 운용 및 국제화 ··················································· 322

    제6장 의약품 안전관리 기반여건 조성 ···································································· 337
    제1절 User fee제도의 도입 ······················································································· 337
    제2절 인력의 확충 및 전문성 강화 ·········································································· 347
    제3절 ICH의 흐름에 따른 국제적 조화 ····································································· 353
    제4절 안전관리 실무기술 연구 촉진 ········································································ 381
    제5절 안전정보 지식망 구축 및 지식 경영 ······························································ 385

    제7장 결 론 ················································································································ 392
    제1절 의약품 안전관리 단계별 중점 추진목표 ························································ 392
    제2절 지표로 본 미래의 의약품 안전관리 모습 ······················································· 395
    제3절 안전관리 파라다임의 전환 ·············································································· 405

    제8장 연구개발목표 달성도 및 대외기여도 ····························································· 407

    제9장 연구개발결과의 활용성 및 계획 ···································································· 408

    제10장 기타 중요변경사항 ······················································································· 409

    제11장 참고문헌 ······································································································· 410

    부 록 ··························································································································· 413

    총괄 연구과제 요약 ··································································································· 417
초록
    □ 연구 목적

    우리나라 의약품 안전관리 현황과 문제점을 품질(Quality)·안전성(Safety)·유
    효성(Efficacy)의 안전관리 요소별로 분석하고, ICH 동향 및 미국·일본 등 선
    진 주요 외국의 의약품 안전관리제도와 비교함으로써, 향후 의약 선진국 진입
    을 위한 제도개선 방향 및 분야를 제시한다.

    □ 주요 연구 결과

    과학기술 발달에 의한 첨단기술제품의 출현, ICH의 국제 조화 동향, 소비자
    주권주의의 강화 등 국내외 여건변화에 능동적으로 대처하기 위해서는 첫째,
    안전관리 정책의 기본 패러다임을 공급자 중심으로부터 소비자의 안전을 최우
    선으로 하면서 산업을 육성하는 방향으로 전환해야 한다. 둘째 과거 외국자료
    에 의한 모방적 안전관리에서 과학적 근거에 의한 창의적·탄력적 안전관리
    (Scientific Flexbility)로 개선해야 한다. 셋째, 리스크(Risk) 평가에 근거하여
    의약품 안전관리 수행체계의 효율성을 제고해야 한다. 이를 위하여 원료 및
    공정관리까지 포함하는 총체적인 품질시스템(Quality System)을 확립해야 하
    며, 시판후 의약품 안전관리(PMS)를 강화하고 안전성 정보가 정부·기업·보건
    의료인·소비자간에 원활히 교류될 수 있는 지식공유체계를 구축해야 한다. 또
    한 안전관리제도는 세분화·전문화됨과 동시에 의약품 안전 확보를 통한 국민
    건강 증진이라는 목표를 향하여 상호 통합·연계관리되어야 한다.
주제어
발행년도 2004

연구결과 평가 및 활용보고서

평가결과서, 활용결과보고서의 정보를 제공합니다.
평가결과서
활용결과 보고서

공공누리 정보